Physician profile
Farhad X Aduli
NPI 1023051372
$6,362.68
in general payments reported to CMS, 2019-2025
42 companies · $773 in 2025
The $773 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $872 · 2021: $1,140 · 2022: $1,253 · 2023: $821 · 2024: $324 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903 · Travel and Lodging: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.96 |
| Travel and Lodging | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $650.35 | 2021-2025 | Selectsecure, Azure Xt Dr Mri Surescan, Linq II |
| Abbott Laboratories | $607.21 | 2019-2024 | Amplatzer Talisman, Jot Dx, Merlin@Home |
| Janssen Pharmaceuticals, INC | $524.83 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $455.98 | 2019-2022 | |
| Novo Nordisk INC | $420.73 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $370.12 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $355.08 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $307.34 | 2019-2022 | |
| Pfizer INC. | $286.43 | 2019-2025 | |
| Medtronic Vascular, INC. | $271.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $268.42 | 2019-2025 | |
| Abiomed | $262.90 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $222.58 | 2019-2022 | |
| Amgen INC. | $205.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.96 | 2019-2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $137.36 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $88.35 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $65.86 | 2021-2025 | Verquvo, Belsomra |
| Angiodynamics, INC. | $64.85 | 2023 | Auryon Laser System 100-120 Vac |
| Esperion Therapeutics, INC. | $58.91 | 2021-2023 | Nexletol |
| Tactile Systems Technology INC | $51.71 | 2021 | |
| Chiesi USA, INC. | $51.21 | 2019 | |
| Boston Scientific Corporation | $44.89 | 2020-2023 | Varithena Administration Pack |
| Baxter Healthcare | $42.57 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Shockwave Medical, INC | $35.96 | 2022 | |
| Vifor Pharma, INC. | $32.65 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $30.57 | 2021 | |
| Celonova Biosciences, INC. | $29.85 | 2019 | |
| Edwards Lifesciences Corporation | $27.23 | 2025 | |
| Atricure, INC. | $26.42 | 2022 | |
| Philips North America LLC | $22.80 | 2023 | |
| Contego Medical, INC | $22.09 | 2025 | |
| Astellas Pharma US INC | $19.68 | 2021 | |
| Impulse Dynamics (USA) INC. | $19.16 | 2021 | |
| Bardy Diagnostics, INC. | $18.43 | 2020 | |
| Glaxosmithkline, LLC. | $17.48 | 2023 | Trelegy Ellipta |
| Bard Peripheral Vascular, INC. | $15.77 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.09 | 2023 | Arcalyst |
| Silk Road Medical, INC. | $14.61 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Kiniksa Pharmaceuticals International, Plc | $13.36 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $12.78 | 2022 | |
| Cmp Pharma, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Aduli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.